Endotoxins (lipopolysaccharides, LPS) are pyrogenic components of Gram-negative bacterial cell walls that can cause fever, sepsis, and death when present in injectable products. This protocol covers endotoxin testing methods, removal strategies, and regulatory requirements for therapeutic peptides.
Component Structure Function Lipid A Disaccharide + fatty acids Primary pyrogenic moiety Core polysaccharide KDO, heptose Structural support O-antigen Repeat polysaccharide Serotype specificity
Endotoxin Source Potency (EU/mg) Application E. coli O111:B4 1,000,000–5,000,000 Reference standard E. coli O55:B5 500,000–2,000,000 Research use S. abortus equi 1,000,000–3,000,000 Alternative standard
Product Type Endotoxin Limit Calculation Injectable (IV) <5 EU/kg/hr Patient weight × infusion rate Injectable (IM) <5 EU/dose Per dose Injectable (SC) <5 EU/dose Per dose Intrathecal <0.2 EU/mL Most restrictive Ophthalmic <0.5 EU/mL Very restrictive
Method Principle Sensitivity Application Gel-clot Gel formation 0.03–0.5 EU/mL Qualitative/semi-quantitative Turbidimetric Turbidity increase 0.005–50 EU/mL Quantitative Chromogenic Color development 0.005–50 EU/mL Quantitative Recombinant Factor C Fluorescence 0.001–10 EU/mL Alternative (no animal)
Step Action Duration Notes 1 Reconstitute LAL reagent 10 min Room temperature 2 Prepare standard curve 5 min 0.5, 0.25, 0.125, 0.06 EU/mL 3 Prepare sample dilutions 10 min 1:1, 1:10, 1:100, 1:1000 4 Mix LAL + sample/standard 10 sec Gentle mixing 5 Incubate at 37°C 60 min Do not disturb 6 Invert tubes 1 sec Read gel formation 7 Record results — Positive/negative
Step Action Duration Notes 1 Reconstitute LAL reagent 10 min Room temperature 2 Prepare standard curve 5 min 0.5, 0.25, 0.125, 0.06 EU/mL 3 Prepare sample dilutions 10 min As needed 4 Mix LAL + sample/standard 10 sec Gentle mixing 5 Incubate at 37°C 60 min Monitor OD 6 Measure turbidity at 340 nm Continuous Kinetic reader 7 Calculate endotoxin concentration — Standard curve
Step Action Duration Notes 1 Reconstitute LAL reagent 10 min Room temperature 2 Prepare standard curve 5 min 0.5, 0.25, 0.125, 0.06 EU/mL 3 Prepare sample dilutions 10 min As needed 4 Mix LAL + sample/standard 10 sec Gentle mixing 5 Incubate at 37°C 10–60 min Kinetic or end-point 6 Add substrate (Ac-Leu-Arg-pNA) — Color development 7 Measure absorbance at 405 nm — Standard curve
Interference Effect Test Solution Enhancement Falsely high result All Dilute sample Inhibition Falsely low result All Dilute sample, addition Masking Cannot detect endotoxin Gel-clot Use alternative method
Step Action Purpose 1 Test sample at multiple dilutions Detect interference 2 Perform spike recovery test Quantify interference 3 Calculate percent recovery 50–200% acceptable 4 If outside range, dilute further Overcome interference
% Recovery = (Measured endotoxin in spiked sample - Measured endotoxin in unspiked sample) / Spiked endotoxin × 100
Acceptable range: 50–200% (FDA), 50–200% (EU GMP)
Interference Source Effect on LAL Solution High salt concentration Inhibition Dilute below toxic level Surfactants (PS-80) Variable Dilution, dialysis EDTA/chelators Inhibition Add Ca²⁺/Mg²⁺ Extreme pH Inhibition Neutralize to pH 6–8 Proteins (high conc.) Inhibition Dilution Peptides (cationic) Enhancement Dilution, polymyxin B Solvents (alcohol) Inhibition Evaporation
Method Mechanism Efficiency Application Ultrafiltration (10 kDa) Size exclusion 90–99% Large peptides/proteins Nanofiltration (10–100 kDa) Size exclusion 95–99% Medium peptides Endotoxin removal filters Adsorption 95–99% Specific applications
Method Mechanism Efficiency Application Polymyxin B affinity LPS binding 95–99% Research use Anion exchange Electrostatic adsorption 80–95% Protein purification HIC (hydrophobic) Hydrophobic interaction 70–90% Purification step Activated carbon Adsorption 80–95% Small molecules
Method Mechanism Efficiency Application Acid treatment (pH 2) Lipid A hydrolysis 90–99% Research use Alkaline treatment Lipid A hydrolysis 80–95% Research use Triton X-114 phase separation Detergent extraction 80–95% Research use
Step Action Conditions Notes 1 Prepare peptide solution 1–10 mg/mL In endotoxin-free WFI 2 Select membrane MWCO <0.5× peptide MW 10 kDa for 20 kDa peptide 3 Concentrate 10× — Remove >90% endotoxin 4 Dilute with endotoxin-free WFI Original volume Exchange buffer 5 Repeat concentration 2–3× Improve removal 6 Test endotoxin level LAL test Confirm removal
Parameter LAL rFC Advantage Animal origin Yes (horseshoe crab) No (recombinant) rFC: No animal use Sensitivity 0.005–0.5 EU/mL 0.001–10 EU/mL rFC: Wider range Specificity LPS + β-glucans LPS only rFC: More specific Cost Moderate Higher LAL: Lower cost Regulatory acceptance Established Growing Both acceptable
Step Action Duration Notes 1 Reconstitute rFC reagent 10 min Room temperature 2 Prepare standard curve 5 min As per kit instructions 3 Prepare sample dilutions 10 min As needed 4 Mix rFC + sample/standard 10 sec Gentle mixing 5 Incubate at 37°C 60 min Fluorescence develops 6 Measure fluorescence — Ex 380 nm, Em 440 nm 7 Calculate endotoxin concentration — Standard curve
Challenge Cause Solution Enhancement (false positive) LPS-LAL interaction potentiation Dilution, polymyxin B neutralization Inhibition High positive charge masks LPS Dilution below interfering level Adsorption to surfaces Electrostatic binding Use low-binding surfaces
Challenge Cause Solution Aggregation with LPS Hydrophobic interaction Surfactant (PS-80) addition Membrane adsorption Hydrophobic binding Use glass or low-binding plastic Poor solubility Hydrophobic sequence Co-solvent or cyclodextrin
Challenge Cause Solution LPS co-purification Large LPS aggregates Ultrafiltration Inhibition in LAL High protein concentration Dilution Recovery issues Adsorption to filters Low-binding filters
Requirement Description Documentation Endotoxin testing Each lot tested LAL test report Endotoxin limits <5 EU/kg/hr (IV) Calculation sheet Test validation Demonstrate method suitability Validation report Interference testing Confirm no interference Spike recovery data
Requirement Description Documentation Endotoxin limits Per Ph. Eur. Test report Method validation Demonstrate suitability Validation report Alternative methods rFC acceptable with justification Comparative data Batch release Endotoxin test results Batch record
Step Action Acceptance Documentation 1 Method selection Appropriate method Method selection rationale 2 Interference testing 50–200% recovery Spike recovery data 3 Positive product control 50–200% recovery PPC data 4 Standard curve r² >0.98 Curve data 5 Sensitivity confirmation Within 2× labeled sensitivity Confirmation data 6 Batch testing Below limits Test report
Stage Test Frequency Acceptance Raw materials Endotoxin Each lot Below limit In-process Endotoxin Critical steps Monitor trend Final product Endotoxin Each batch <5 EU/kg/hr Stability Endotoxin Per protocol Within spec Environmental Endotoxin Per schedule Monitor trend
Cooper JF. “Resolving LAL test interferences.” PDA J Pharm Sci Technol 1990;44:13-16.
Dubczak J. “Evaluation of LAL testing of peptide and protein products.” PDA J Pharm Sci Technol 1998;52:59-65.
Roslansky PF, Novitsky TJ. “Sensitivity of Limulus amebocyte lysate (LAL) to LAL-reactive substances.” J Clin Microbiol 1991;29:1275-1279.
Piehler M, et al. “Recombinant Factor C assay for endotoxin detection.” Eur J Pharm Biopharm 2020;154:236-245.
FDA. “Pyrogen and endotoxins testing.” Guidance for Industry 2012.
